- Price
- $6.53
- Day
- -1.21%
- Mkt Cap
- $2.33B
- 52W Range
- $1.70 – $6.80
- Volume
- 8.02M
- Beta
- 1.01
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Precigen, Inc. (PGEN) Q2 2026 Earnings Call Transcript
Read full article
Precigen NASDAQ: PGEN reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy's August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP.
Read full article
PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and broad US adoption PAPZIMEOS revenue propelled the Company to quarterly profitability Cash, cash equivalents, and investments totaled $38.7 million as of June 30, 2026, which together with proceeds from PAPZIMEOS revenue, is expected to support cash flow break-even by the end of 2026 PAPZIMEOS patient hub enrollment reached well over 500 patients across major centers and community practices, demonstrating expanding reach and ease of administration across treatment settings FDA granted PAPZIMEOS seven-year market exclusivity, providing long-term protection against prospective competition Conference call scheduled for 4:30 PM ET today GERMANTOWN, Md., Aug. 4, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced second quarter 2026 financial results and business updates.
Read full article
Precigen, Inc. (PGEN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.11 per share a year ago.
Read full article
GERMANTOWN, Md., July 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026.
Read full article
CFO Harry Thomasian Jr. sold 200,000 shares of Precigen common stock across two transactions for a total value of approximately $1.11 million, based on a weighted average price of $5.57 per share. This transaction reduced his direct ownership by 36%, leaving him with 354,535 shares directly held post-sale, representing an estimated $1.86 million as of the July 1, 2026 market close.
Read full article